Literature DB >> 4884278

Commentary on incidence of primary aldosteronism: current estimations based on objective data.

N M Kaplan.   

Abstract

Mesh:

Substances:

Year:  1969        PMID: 4884278

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


× No keyword cloud information.
  8 in total

Review 1.  Primary aldosteronism: rare bird or common cause of secondary hypertension?

Authors:  M Stowasser
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 2.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 3.  Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

4.  Remission of primary hyperaldosteronism consequent on adrenal venography.

Authors:  P E Teixeira; D E Dwyer; G W Viol
Journal:  Can Med Assoc J       Date:  1977-10-08       Impact factor: 8.262

Review 5.  Primary aldosteronism: are we diagnosing and operating on too few patients?

Authors:  R D Gordon; M Stowasser; J C Rutherford
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

6.  Fecal and salivary electrolytes in the diagnosis of primary aldosteronism.

Authors:  D R Wilson; J C Laidlaw; J L Ruse
Journal:  Can Med Assoc J       Date:  1971-12-18       Impact factor: 8.262

7.  Changes in the perceived epidemiology of primary hyperaldosteronism.

Authors:  Riccardo Maria Fagugli; Chiara Taglioni
Journal:  Int J Hypertens       Date:  2011-08-04       Impact factor: 2.420

8.  Changes in the clinical manifestations of primary aldosteronism.

Authors:  Sun Hwa Kim; Jae Hee Ahn; Ho Cheol Hong; Hae Yoon Choi; Yoon Jung Kim; Nam Hoon Kim; Hye Jin Yoo; Hee Young Kim; Ji A Seo; Nan Hee Kim; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi
Journal:  Korean J Intern Med       Date:  2014-02-27       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.